Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ambulatory introduction of foslevodopa/foscarbidopa in Parkinson's disease in private practice. Case series of the first 22 patients.

Revue neurologique·2026
Same author

Short Communication: True Cost Accounting (TCA) as a transformative approach for livestock agri-food systems.

Animal : an international journal of animal bioscience·2025
Same author

The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party.

Bone marrow transplantation·2025
Same author

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Spinocerebellar ataxia 27B (SCA27B), a frequent late-onset cerebellar ataxia.

Revue neurologique·2024
Same author

Megalencephaly secondary to a novel germline missense variant p.Asp322Tyr in AKT3 associated with growth hormone deficiency and central hypothyroidism: A case report.

American journal of medical genetics. Part A·2024

Related Experiment Video

Updated: May 28, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

[Mantle cell lymphoma: management in 2011].

C Bonnet1, J Caers, B De Prijck

  • 1Service d'hématologie clinique, Département de médecine interne, CHU Sart-Tilman, Université de Liège, Belgique. cbonnet@ulg.ac.be

Revue Medicale Suisse
|October 7, 2011
PubMed
Summary

Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma. Treatment varies by age, involving chemotherapy and stem cell transplant, with targeted therapies offering future hope for this malignancy.

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Related Experiment Videos

Last Updated: May 28, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Context:

  • Mantle cell lymphoma (MCL) is a rare, aggressive subtype of non-Hodgkin lymphoma.
  • Diagnosis relies on characteristic immunophenotype and the t(11;14) translocation with cyclin D1 overexpression.

Purpose:

  • To outline current diagnostic criteria for mantle cell lymphoma.
  • To describe established first-line treatment strategies based on patient age.
  • To discuss therapeutic options for relapsed disease and future directions.

Summary:

  • For younger patients, initial treatment involves alternating R-CHOP21 and R-DHAP21 regimens, followed by autologous stem cell transplant conditioned with irradiation and chemotherapy.
  • Older patients (over 65) typically receive 8 cycles of R-CHOP21.
  • Allogeneic stem cell transplantation is the primary curative option for relapsed MCL in eligible patients; maintenance therapies are under investigation.

Impact:

  • Establishes current standards of care for mantle cell lymphoma diagnosis and treatment.
  • Highlights the role of autologous and allogeneic stem cell transplantation.
  • Points towards targeted therapies as a promising avenue for improving patient outcomes and prognosis in mantle cell lymphoma.